版本:
中国

BRIEF-Ligand enters into worldwide Omniab platform license agreement with Surface Oncology

June 1 Ligand Pharmaceuticals Inc

* Ligand enters into worldwide Omniab® platform license agreement with Surface Oncology

* Has entered into a worldwide license agreement with Surface Oncology

* Ligand Pharmaceuticals - under license, Surface will use omnirat, omnimouse, omniflic platforms to discover fully human mono- and bispecific antibodies

* Surface will be responsible for all costs related to programs Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐